Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
Status:
Recruiting
Trial end date:
2023-08-02
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of leflunomide in treating patients with steroid
dependent chronic graft versus host disease (cGVHD). cGVHD is a common complication of bone
marrow transplant. GVHD occurs when immune cells transplanted from a donor (the graft)
recognize the transplant recipient (the host) as foreign, and cause damage to the skin,
gastrointestinal tract or other organs. Steroids are the first line of therapy and benefits
are seen in about one-third of patients with cGVHD. Prolonged use of steroids is associated
with multiple complications. Leflunomide may decrease the body's immune response and reduce
inflammation associated with cGVHD.